α-Synuclein-Degrading Catalytide for Parkinson’s Disease (in vivo validated)

We are advancing a catalytic peptide platform (Catalytide) for the treatment of Parkinson’s disease by directly degrading pathogenic α-synuclein aggregates.

Our lead program has demonstrated robust in vivo efficacy, including both functional improvements and significant reduction of pathological aggregates in validated Parkinson’s disease models. We also evaluated CNS drug delivery via nasal administration in mice and monkey and confirmed reduced p-α-Syn positive aggregates in PD brain specimens treated with Catalytides (in vitro)

Unlike conventional approaches such as antibodies or small-molecule inhibitors, Catalytides act catalytically, enabling degradation of disease-causing proteins and offering a differentiated strategy for disease modification.

Built on our integrated workflow—aggregation core identification, rational peptide design, and pharmacological validation—this platform enables efficient generation of disease-targeting Catalytides with therapeutic potential.

We are actively seeking strategic partners for:

• Licensing of α-synuclein-targeting Catalytide assets

• Collaborative research (PD models, biomarkers, CNS delivery)

• Co-development to accelerate clinical translation

While our primary focus is Parkinson’s disease, the platform is readily expandable to other neurodegenerative targets, including Amyloid-beta, tau, TDP-43 and SOD1.

We welcome partnerships with pharmaceutical and biotech companies aiming to develop next-generation disease-modifying therapies for neurodegenerative diseases.